IL249058B2 - Improved forms of selective pi3k delta inhibitors for use in pharmaceutical formulations - Google Patents

Improved forms of selective pi3k delta inhibitors for use in pharmaceutical formulations

Info

Publication number
IL249058B2
IL249058B2 IL249058A IL24905816A IL249058B2 IL 249058 B2 IL249058 B2 IL 249058B2 IL 249058 A IL249058 A IL 249058A IL 24905816 A IL24905816 A IL 24905816A IL 249058 B2 IL249058 B2 IL 249058B2
Authority
IL
Israel
Prior art keywords
salt
disease
lymphoma
tgr
disorder
Prior art date
Application number
IL249058A
Other languages
English (en)
Hebrew (he)
Other versions
IL249058B (en
IL249058A0 (en
Inventor
Swaroop Kumar Venkata Satya Vakkalanka
Original Assignee
Rhizen Pharmaceuticals Sa
Swaroop Kumar Venkata Satya Vakkalanka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals Sa, Swaroop Kumar Venkata Satya Vakkalanka filed Critical Rhizen Pharmaceuticals Sa
Publication of IL249058A0 publication Critical patent/IL249058A0/en
Publication of IL249058B publication Critical patent/IL249058B/en
Publication of IL249058B2 publication Critical patent/IL249058B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL249058A 2014-05-27 2016-11-20 Improved forms of selective pi3k delta inhibitors for use in pharmaceutical formulations IL249058B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2596CH2014 2014-05-27
IN2597CH2014 2014-05-27
PCT/IB2015/053940 WO2015181728A1 (en) 2014-05-27 2015-05-26 Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Publications (3)

Publication Number Publication Date
IL249058A0 IL249058A0 (en) 2017-01-31
IL249058B IL249058B (en) 2022-11-01
IL249058B2 true IL249058B2 (en) 2023-03-01

Family

ID=53499042

Family Applications (1)

Application Number Title Priority Date Filing Date
IL249058A IL249058B2 (en) 2014-05-27 2016-11-20 Improved forms of selective pi3k delta inhibitors for use in pharmaceutical formulations

Country Status (22)

Country Link
US (4) US9969740B2 (enExample)
EP (2) EP3971188A1 (enExample)
JP (3) JP6987501B2 (enExample)
KR (1) KR20170007480A (enExample)
CN (2) CN106661030B (enExample)
AU (1) AU2015265542B2 (enExample)
BR (1) BR112016027674A2 (enExample)
CA (1) CA2949932C (enExample)
CY (1) CY1124316T1 (enExample)
DK (1) DK3149000T3 (enExample)
EA (1) EA032506B1 (enExample)
ES (1) ES2880999T3 (enExample)
HR (1) HRP20211151T1 (enExample)
HU (1) HUE054916T2 (enExample)
IL (1) IL249058B2 (enExample)
LT (1) LT3149000T (enExample)
PL (1) PL3149000T3 (enExample)
PT (1) PT3149000T (enExample)
RS (1) RS62136B1 (enExample)
SI (1) SI3149000T1 (enExample)
SM (1) SMT202100532T1 (enExample)
WO (1) WO2015181728A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3149000T (pt) * 2014-05-27 2021-07-27 Rhizen Pharmaceuticals S A Sal tosilato cristalino de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas
CA3024123A1 (en) 2016-05-27 2017-11-30 Tg Therapeutics, Inc. Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders
BR112019004185A2 (pt) 2016-09-09 2019-09-03 Lab Francais Du Fractionnement combinação de um anticorpo anti-cd20, inibidor de pi3-quinase-delta inibidor e anticorpo anti-pd-1 ou anti-pd-l1 para tratamento de cânceres hematológicos
CA3146785A1 (en) * 2019-07-15 2021-01-21 Johnson Matthey Public Limited Company Amorphous umbralisib monotosylate
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014006572A1 (en) * 2012-07-04 2014-01-09 Rhizen Pharmaceuticals Sa Selective pi3k delta inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1278748B1 (en) 2000-04-25 2011-03-23 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
BRPI0316779B1 (pt) 2002-12-16 2020-04-28 Genentech Inc anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
US20100202963A1 (en) 2008-11-13 2010-08-12 Gallatin W Michael Therapies for hematologic malignancies
CN102439012A (zh) 2009-03-24 2012-05-02 吉里德卡利斯托加公司 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法
CA2759724A1 (en) 2009-04-20 2010-10-28 Calistoga Pharmaceuticals, Inc. Methods of treatment for solid tumors
PT3149000T (pt) * 2014-05-27 2021-07-27 Rhizen Pharmaceuticals S A Sal tosilato cristalino de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014006572A1 (en) * 2012-07-04 2014-01-09 Rhizen Pharmaceuticals Sa Selective pi3k delta inhibitors

Also Published As

Publication number Publication date
JP6987501B2 (ja) 2022-01-05
JP2022082680A (ja) 2022-06-02
IL249058B (en) 2022-11-01
SI3149000T1 (sl) 2021-09-30
PT3149000T (pt) 2021-07-27
HUE054916T2 (hu) 2021-10-28
US10414773B2 (en) 2019-09-17
IL249058A0 (en) 2017-01-31
DK3149000T3 (da) 2021-08-30
PL3149000T3 (pl) 2021-11-02
US20210269446A1 (en) 2021-09-02
EP3149000A1 (en) 2017-04-05
RS62136B1 (sr) 2021-08-31
AU2015265542B2 (en) 2019-05-09
US20170121336A1 (en) 2017-05-04
BR112016027674A2 (pt) 2017-08-15
AU2015265542A1 (en) 2016-12-08
EP3971188A1 (en) 2022-03-23
HRP20211151T1 (hr) 2021-10-15
LT3149000T (lt) 2021-09-10
US10947244B2 (en) 2021-03-16
US20190016725A1 (en) 2019-01-17
CA2949932C (en) 2021-08-10
JP2020122022A (ja) 2020-08-13
US9969740B2 (en) 2018-05-15
EA201692255A1 (ru) 2017-04-28
JP2017516785A (ja) 2017-06-22
CY1124316T1 (el) 2022-07-22
CA2949932A1 (en) 2015-12-03
CN106661030B (zh) 2020-06-30
EA032506B1 (ru) 2019-06-28
EP3149000B1 (en) 2021-06-30
KR20170007480A (ko) 2017-01-18
CN111635406A (zh) 2020-09-08
CN106661030A (zh) 2017-05-10
SMT202100532T1 (it) 2021-11-12
ES2880999T3 (es) 2021-11-26
WO2015181728A1 (en) 2015-12-03
US20190382411A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
US10414773B2 (en) Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
EP3153170B1 (en) Methods and uses of the quinoline derivative anlotinib in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same
JP2024533423A (ja) 薬学的組成物およびその使用
CN109988104B (zh) 山奈酚与异烟酰胺共晶物及制备方法和其药物组合物与用途
CN106659761A (zh) 初级癌症疗法后使用的含硼蛋白酶体抑制剂
CN111840289A (zh) 用于治疗骨巨细胞瘤的喹啉类化合物或其药学上可接受的盐
CN101912399B (zh) 放射线治疗增强剂
CN115124420B (zh) 大黄酸与苦参碱共晶物水合物及制备方法和其组合物与用途
HK1236026B (en) Crystalline tosylate salt of a pi3k delta selective inhibitor for use in pharmaceutical formulations
CA3218977A1 (en) A plurality of tasquinimod particles and use thereof
EA042667B1 (ru) Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах
KR20230026415A (ko) 경구 제제 및 이의 용도
HK40110967A (zh) 药物组合物及其用途
WO2019130194A1 (en) Novel drug products of picropodophyllin
HK40115442A (zh) 3-((1r，3r)-1-(2，6-二氟-4-((1-(3-氟丙基)氮杂环丁烷-3-基)氨基)苯基)-3-甲基-1，3，4，9-四氢-2h-吡啶并[3，4-b]吲哚-2-基)-2，2-二氟丙-1-醇酒石酸盐的固体形式
EA040951B1 (ru) Лекарственные формы цис-4-[2-{[(3s,4r)-3-фтороксан-4-ил]амино}-8-(2,4,6-трихлоранилино)-9н-пурин-9-ил]-1-метилциклогексан-1-карбоксамида и их применение в способе лечения рака
HK1118704B (en) Radiotherapy enhancer
HK1118807B (en) Potentiator for radiation therapy comprising pyridine derivative as active ingredient
HK1118807A1 (en) Potentiator for radiation therapy comprising pyridine derivative as active ingredient